Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $546.3 million.

  • United Therapeutics' Total Non-Current Liabilities fell 3745.13% to $546.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.3 million, marking a year-over-year decrease of 3745.13%. This contributed to the annual value of $738.1 million for FY2024, which is 3316.73% down from last year.
  • As of Q3 2025, United Therapeutics' Total Non-Current Liabilities stood at $546.3 million, which was down 3745.13% from $527.1 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Total Non-Current Liabilities registered a high of $1.2 billion during Q3 2023, and its lowest value of $527.1 million during Q2 2025.
  • Over the past 5 years, United Therapeutics' median Total Non-Current Liabilities value was $1.1 billion (recorded in 2023), while the average stood at $998.2 million.
  • As far as peak fluctuations go, United Therapeutics' Total Non-Current Liabilities skyrocketed by 1148.85% in 2023, and later tumbled by 4346.24% in 2025.
  • Quarter analysis of 5 years shows United Therapeutics' Total Non-Current Liabilities stood at $1.1 billion in 2021, then rose by 3.42% to $1.1 billion in 2022, then dropped by 3.39% to $1.1 billion in 2023, then crashed by 33.17% to $738.1 million in 2024, then fell by 25.99% to $546.3 million in 2025.
  • Its last three reported values are $546.3 million in Q3 2025, $527.1 million for Q2 2025, and $721.5 million during Q1 2025.